The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering

202449 citationsJournal Articlehybrid Open Access

Authors

Michelle L. O’Donoghue · Brigham and Women's Hospital

Robert S. Rosenson · Mount Sinai Hospital

J. Antonio G. López · Amgen (United States)

Norman E. Lepor · University of California, Los Angeles

Seth J. Baum · Florida Atlantic University

Elmer Stout · CrossRoads Extremity Systems (United States)

Daniel Gaudet

Abstract

Olpasiran is a potent siRNA with prolonged effects on Lp(a) lowering. Participants receiving doses ≥75 mg Q12W sustained a ∼40% to 50% reduction in Lp(a) levels close to 1 year after the last dose. (Olpasiran Trials of Cardiovascular Events And LipoproteiN[a] Reduction-DOSE Finding Study [OCEAN(a)-DOSE]; NCT04270760).

Topics & Keywords

Lipoproteins and Cardiovascular Health Hormonal Regulation and Hypertension Antioxidant Activity and Oxidative Stress

UN Sustainable Development Goals

Clean water and sanitation

Publication Details

Published in: Journal of the American College of Cardiology

Volume 84, Issue 9, pp. 790-797

DOI: 10.1016/j.jacc.2024.05.058

Field-Weighted Citation Impact: 27.70